HIGHLIGHTS
- who: HSIL HPV and colleagues from the Department of Gynecology, Leiden University Medical Center, Leiden, The Netherlands have published the paper: A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions, in the Journal: (JOURNAL)
- what: The aim of this study was to investigate the capacity of an E6/E7 synthetic overlapping longpeptide vaccine to stimulate the HPV16-specific T-cell response to enhance the infiltration of HPV16-specific type T cells into the lesions of patients with high-grade cervical squamous intraepithelial lesion (HSIL) and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.